Today it was reported that a Director at Momenta Pharma (NASDAQ: MNTA), James Sulat, exercised options to buy 13,500 MNTA shares at $14.79 a share, for a total transaction value of $199.7K. The options were close to expired and James Sulat retained stocks.
Following this transaction James Sulat’s holding in the company was increased by 51.46% to a total of $1.03 million. Following James Sulat’s last MNTA Buy transaction on October 20, 2014, the stock climbed by 14.7%.
See today’s analyst top recommended stocks >>
Currently, Momenta Pharma has an average volume of 325.4K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection.
